- Home
- Automated
- List of product information
- FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN) [SIN16043P]
FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN) [SIN16043P]
Active ingredients: FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)
Last updated 26 October 2025
On this page
Product Info
FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN)
[SIN16043P]
Product information
Active Ingredient and Strength | BENRALIZUMAB - 30 MG/ML |
Dosage Form | INJECTION, SOLUTION |
Manufacturer and Country | CATALENT INDIANA, LLC - UNITED STATES |
Registration Number | SIN16043P |
Licence Holder | ASTRAZENECA SINGAPORE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | R03DX10 |
4.1 Therapeutic indication
FASENRA is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
4.2 Posology and method of administration
Posology
The recommended dose is 30 mg of FASENRA by subcutaneous injection every 4 weeks for the first 3 doses, and then every 8 weeks thereafter.
FASENRA is intended for long-term treatment. A decision to continue the therapy should be made at least annually based on disease severity, level of exacerbation control and blood eosinophil counts.
Paediatric population
Available data of FASENRA in adolescents aged 12 to less than 18 years are described in section 5.1, however no posology recommendations can be made – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
The safety and efficacy of FASENRA in children aged less than 12 years have not been established.
Elderly patients
No dose adjustment is required for elderly patients (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Renal and hepatic impairment
No dose adjustment is required for patients with renal or hepatic impairment (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Method of administration
FASENRA is administered as a subcutaneous injection. In line with clinical practice, monitoring of patients after administration of biologic agents is recommended (see section 4.4, Hypersensitivity Reactions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Administer FASENRA into the thigh, or abdomen. If somebody else administers the injection, the upper arm can also be used. Do not administer into areas where the skin is tender, bruised, erythematous, or hardened.
After proper training in the subcutaneous injection technique and education about signs and symptoms of hypersensitivity reactions (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information), patients or their caregivers may administer Fasenra if their physician determines that it is appropriate, with medical follow-up as necessary. Proper training in subcutaneous injection technique using the autoinjector (FASENRA PEN) should be provided according to the ‘Instructions for Use’ – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
4.3 Contraindications
FASENRA is contraindicated in patients who have known hypersensitivity to benralizumab or any of its excipients (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).